While semaglutide and tirzepatide focus primarily on GLP-1 and GIP pathways, this peptide also activates the glucagon receptor, which boosts energy expenditure and weight reduction
According to ScienceAlert, This equates to around 7.6 million fewer people being counted as obese compared to three years ago, meaning a potential future reduction in obesity-related health conditions, including cancer, heart disease, stroke and mental health issues. Gallup found that this year nearly 10% of men and just over 15% of women are using semaglutide or liraglutide drugs, which are all GLP-1s
In 2023, Wang Z., et al
Marcolin ML, Tarot A, Lombardo V, Pereira B, Lander AV, Guastella V
Retatrutide has been investigated in research for its effects on metabolic regulation, appetite pathways, and weight management studies
Even so, most large trials were global, so more India-specific research will help confirm how strongly the GLP-1 heart benefits and GLP-1 kidney benefits apply locally